
    
      Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter,
      multi-national study to assess the efficacy, safety and tolerability, and pharmacokinetics
      (PK) of INS1007 administered once daily for 24 weeks in subjects with non-cystic fibrosis
      bronchiectasis (NCFBE).
    
  